Guangzhou Wondfo Biotech Co Ltd

Guangzhou Wondfo Biotech Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.11 and a current ratio of 3.18, indicating strong short-term liquidity coverage. The company holds total equity of CNY 5.41 billion against total liabilities of CNY 1.19 billion, with long-term debt standing at CNY 612.8 million. Despite a negative net cash position after subtracting total debt, the firm generated positive operating cash flow of CNY 463.0 million, which partially offsets a free cash flow deficit of CNY 308.4 million driven by capital expenditures of CNY 304.6 million. The market capitalization is CNY 7.72 billion, trading at a price-to-book ratio of 1.43.

Profitability metrics reflect a period of operational pressure, with the company reporting an operating income loss of CNY 114.9 million and a net income loss of CNY 63.0 million on revenues of CNY 2.09 billion. The return on equity is -1.16% and return on assets is -0.95%, indicating that the current asset base is not generating positive returns for shareholders. The gross profit of CNY 1.18 billion suggests a gross margin of approximately 56.4%, but operating expenses have exceeded this contribution, leading to the net loss. The negative EV/EBITDA of -72.56 underscores the current earnings deficit relative to the enterprise value.

Revenue concentration and segment details are not explicitly provided in the available data, limiting the ability to assess specific product or geographic exposure. The company operates within the Health Care Equipment & Supplies industry according to sector classification codes, suggesting a focus on diagnostic equipment or related supplies. Without specific segment breakdowns, the revenue base of CNY 2.09 billion is treated as a consolidated figure for analysis.

Growth trajectory analysis is constrained by the absence of historical period data in the input, preventing a year-over-year or quarter-over-quarter trend assessment. The current revenue figure of CNY 2.09 billion serves as the baseline for the latest normalized period. The significant capital expenditure of CNY 304.6 million suggests ongoing investment in capacity or R&D, which may support future growth but currently impacts free cash flow.

Risk assessment indicates medium liquidity risk and low dilution risk, with a key flag noting that net cash is negative after subtracting total debt. The company’s ability to service its long-term debt of CNY 612.8 million is supported by its strong current ratio of 3.18, but the negative free cash flow requires monitoring. The low dilution risk suggests that the share count of 468.1 million shares is stable, with no immediate signs of aggressive equity issuance.

Recent events and filing observations are not detailed in the available data, limiting the context for recent strategic shifts or market reactions. The company’s valuation at 3.99x EV/Revenue reflects the market’s pricing of its current earnings challenges against its revenue base. Investors should monitor the company’s ability to convert its gross profit into operating income and improve free cash flow generation.